1-(3,5-dibromo-4-hydroxyphenyl)-3-phenylurea | 1070241-14-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,5-dibromo-4-hydroxyphenyl)-3-phenylurea
• CAS: 1070241-14-3
• 化学式: C₁₃H₁₀Br₂N₂O₂
• 分子量: 386.043
• InChiKey: SNNIBBXRTTWZTB-UHFFFAOYSA-N

物化性质

• 沸点：
  340.1±42.0 °C(Predicted)
• 密度：
  1.923±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-氨基-2,6-二溴苯酚 、 异氰酸苯酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以91%的产率得到1-(3,5-dibromo-4-hydroxyphenyl)-3-phenylurea
  参考文献：
  名称：

  Toward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies

  摘要：

  To develop potent and highly selective transthyretin (TTR) amyloidogenesis inhibitors, it is useful to systematically optimize the three substructural elements that compose a typical TTR kinetic stabilizer: the two aryl rings and the linker joining them. Herein, we evaluated 40 bisaryl molecules based on 10 unique linker substructures to determine how these linkages influence inhibitor potency and selectivity. These linkers connect one unsubstituted aromatic ring to either a 3,5-X 2 or a 3,5-X 2-4-OH phenyl substructure (X = Br or CH 3). Coconsideration of amyloid inhibition and ex vivo plasma TTR binding selectivity data reveal that direct connection of the two aryls or linkage through nonpolar E-olefin or -CH 2CH 2- substructures generates the most potent and selective TTR amyloidogenesis inhibitors exhibiting minimal undesirable binding to the thyroid hormone nuclear receptor or the COX-1 enzyme. Five high-resolution TTR.inhibitor crystal structures (1.4-1.8 A) provide insight into why such linkers afford inhibitors with greater potency and selectivity.

  DOI：

  10.1021/jm800435s

文献信息

• New compounds for the inhibition of rotamases and use thereof
  申请人：Jerini AG

  公开号：EP2100876A2

  公开（公告）日：2009-09-16

  The present invention is related to a compound of the formula (I): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising - C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -S(O)-, -S(O2)-, -S(O)-NR13-, and -S(O2)-NR14-, -O-, -S- or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl , substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及一种式 (I) 的化合物： 其中 Z1、Z2、Z3 和 Z4 各自独立地选自包括 -C(O)-、-C(S)-、-C(O)-NR10-、-C(S)-NR11-、-C(N-CN)-NR12-、-S(O)-、-S(O2)-、-S(O)-NR13- 和 -S(O2)-NR14-、-O-、-S- 或各自独立地不存在的组；X 是间隔物，独立地选自包括-M1-L1-K-L2-M2-在内的组，其中 Y 选自包括烷基、取代烷基、直链烷基、取代直链烷基、支链烷基、取代支链烷基、直链烯基、取代直链烯基、支链烯基、取代支链烯基、直链炔基、取代直链炔基、支链炔基、取代支链炔基、环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、环烷基、取代环烷基、环烯基、取代环烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代的多不饱和杂环基、单取代的单不饱和杂环基、多取代的单不饱和杂环基、芳基、取代的芳基、杂芳基和取代的杂芳基，其中 Y 不同于肽或不存在。
• Toward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies
  作者：Steven M. Johnson、Stephen Connelly、Ian A. Wilson、Jeffery W. Kelly

  DOI：10.1021/jm800435s

  日期：2008.10.23

  To develop potent and highly selective transthyretin (TTR) amyloidogenesis inhibitors, it is useful to systematically optimize the three substructural elements that compose a typical TTR kinetic stabilizer: the two aryl rings and the linker joining them. Herein, we evaluated 40 bisaryl molecules based on 10 unique linker substructures to determine how these linkages influence inhibitor potency and selectivity. These linkers connect one unsubstituted aromatic ring to either a 3,5-X 2 or a 3,5-X 2-4-OH phenyl substructure (X = Br or CH 3). Coconsideration of amyloid inhibition and ex vivo plasma TTR binding selectivity data reveal that direct connection of the two aryls or linkage through nonpolar E-olefin or -CH 2CH 2- substructures generates the most potent and selective TTR amyloidogenesis inhibitors exhibiting minimal undesirable binding to the thyroid hormone nuclear receptor or the COX-1 enzyme. Five high-resolution TTR.inhibitor crystal structures (1.4-1.8 A) provide insight into why such linkers afford inhibitors with greater potency and selectivity.